...
首页> 外文期刊>Revista Espaola de Enfermedades Digestivas >Esofagitis eosinofílica respondedora a los inhibidores de la bomba de protones: perspectiva histórica sobre una entidad nueva y en desarrollo
【24h】

Esofagitis eosinofílica respondedora a los inhibidores de la bomba de protones: perspectiva histórica sobre una entidad nueva y en desarrollo

机译:质子泵抑制剂反应性嗜酸性食管炎:关于一个新的和正在发展的实体的历史观点

获取原文

摘要

Eosinophilic esophagitis (EoE) is an emerging chronic esophageal disease, first described in 1993, with a steadily increasing incidence and prevalence in western countries. Over the 80's and early 90's, dense esophageal eosinophilia was mostly associated gastroesophageal reflux disease (GERD). For the next 15 years, EoE and GERD were rigidly considered separate entities: Esophageal eosinophilia with pathological acid exposure on pH monitoring or response to proton pump inhibitor (PPI) therapy was GERD, whereas normal pH monitoring or absence of response to PPIs was EoE. Updated guidelines in 2011 described a novel phenotype, proton pump inhibitor-responsive esophageal eosinophilia (PPI-REE), referring to patients who appear to have EoE clinically, but who achieve complete remission after PPI therapy. Currently, PPI-REE must be formally excluded before diagnosing EoE, since 30-40 % of patients with suspected EoE are eventually diagnosed with PPI-REE. Interestingly, PPI-REE and EoE remain undistinguishable based on clinical, endoscopic, and histological findings, pH monitoring, and measurement of tissue markers and cytokines related to eosinophilic inflammation. This review article aims to revisit the relatively novel concept of PPI-REE from a historical perspective, given the strong belief that only GERD, as an acid peptic disorder, could respond to the acid suppressing ability of PPI therapy, is becoming outdated. Evolving evidence suggests that PPI-REE is genetically and phenotypically undistinguishable from EoE and PPI therapy alone can almost completely reverse allergic inflammation. As such, PPI-REE might constitute a subphenotype of EoE and PPI therapy may be the first therapeutic step and diet/ steroids may represent step up therapy. Possibly, the term PPI-REE will be soon replaced by PPI-responsive EoE. The mechanism as to why some patients respond to PPI therapy (PPI-REE) while others do not (EoE), remains to be elucidated.
机译:嗜酸性食道炎(EoE)是一种新兴的慢性食道疾病,最早于1993年描述,在西方国家发病率和患病率稳步上升。在80年代和90年代初,密集的食道嗜酸性粒细胞增多症主要与胃食管反流病(GERD)相关。在接下来的15年中,EoE和GERD被严格认为是独立的实体:在pH值监测或质子泵抑制剂(PPI)治疗反应中伴有病理性酸暴露的食道嗜酸粒细胞增多症是GERD,而正常pH值监测或对PPIs反应无反应是EoE。 2011年更新的指南描述了一种新的表型,质子泵抑制剂反应性食管嗜酸性粒细胞增多症(PPI-REE),指的是临床上似乎具有EoE但在PPI治疗后完全缓解的患者。目前,在诊断EoE之前必须正式排除PPI-REE,因为30-40%的可疑EoE患者最终被诊断为PPI-REE。有趣的是,根据临床,内镜和组织学发现,pH监测以及与嗜酸性粒细胞炎症相关的组织标志物和细胞因子的测量,PPI-REE和EoE仍然无法区分。鉴于坚信只有GERD作为一种酸性消化系统疾病,才能对PPI疗法的抑酸能力做出响应,因此,这篇综述文章旨在从历史的角度重新审视PPI-REE的相对新颖的概念。不断发展的证据表明,PPI-REE在基因和表型上与EoE没有区别,仅PPI治疗几乎可以完全逆转过敏性炎症。因此,PPI-REE可能构成EoE的亚表型,PPI治疗可能是第一步治疗,饮食/类固醇可能代表逐步治疗。可能,术语PPI-REE将很快被PPI响应EoE取代。关于某些患者为何对PPI治疗有反应(PPI-REE)而其他患者无反应(EoE)的机制,尚待阐明。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号